Table of Contents
- Trial overview
- Who is being studied
- Treatments being tested
- What researchers measure
- Trial phase and status
- What this means for patients
Trial overview
The available study of Mcla-129 is an interventional clinical trial, which means researchers give a treatment and then measure the results.[1] The trial is titled “Phase 1 / 2 Study Evaluating MCLA-129 in Advanced NSCLC,” and the record provided shows it as a Phase 1 study.[1]
This trial is authorised and plans to enroll 287 participants.[1] The condition listed in the record is solid tumors, and the brief summary shows a focus on advanced non-small cell lung cancer, often shortened to NSCLC.[1]
Who is being studied
The trial is aimed at people with advanced NSCLC and other solid tumors.[1] “Advanced” means the cancer is at a later stage and may be more difficult to treat.[1]
The source data do not list the full inclusion and exclusion rules, so the exact participation rules are not shown in the record provided.[1] This means the study population can only be described from the trial summary available here.[1]
Treatments being tested
The trial is studying single-agent Mcla-129, which means Mcla-129 is used by itself in part of the research.[1] It is also being studied in combination with chemotherapy and osimertinib.[1]
The trial record lists the following study drugs: docetaxel, paclitaxel, carboplatin, osimertinib, and Mcla-129.[1] The record does not explain which exact combination each participant receives, but it clearly shows that researchers are comparing Mcla-129 alone and with other cancer treatments.[1]
What researchers measure
The main tumor result being measured is Objective Response Rate (ORR), which shows how many tumors shrink or disappear during treatment.[1] This is one of the most common ways to see early signs that a cancer treatment may work.[1]
Researchers are also tracking safety and tolerability, including the frequency and severity of adverse events, serious adverse events, treatment discontinuations, and treatment modifications.[1] In simple terms, this tells the team how well people can stay on the treatment and whether side effects lead to stopping or changing it.[1]
Another important area is pharmacokinetics, which describes how the body handles the treatment over time.[1] The record lists measures such as CEOI, Cmax, C0h, AUC, CL, Vss, tmax, t1/2, and population pharmacokinetics.[1] These are technical measures that help researchers understand drug levels, exposure, and how quickly the treatment moves through the body.[1]
The trial also measures Progression-Free Survival (PFS), Duration of Response (DOR), and Overall Survival (OS).[1] PFS shows how long the cancer stays from getting worse, DOR shows how long a response lasts, and OS shows how long people live after starting treatment.[1]
Trial phase and status
The study is listed as Phase 1 in the source data.[1] Phase 1 trials usually focus on safety first, while also looking for early signs of benefit.[1]
The status is Authorised, which means the trial has been approved to move forward in the listed setting.[1] The record does not provide a completion date or final results, so the current outcome of the study is not known from the source material.[1]
What this means for patients
This trial is part of early cancer research for people with advanced NSCLC and other solid tumors.[1] It is designed to answer practical questions: does the treatment shrink tumors, is it safe enough to continue, and how does the body process it?[1]
Because the study includes both Mcla-129 alone and Mcla-129 with other cancer medicines, the researchers are trying to learn whether the treatment may work differently in combination settings.[1] The available record gives a clear early-stage research picture, but not detailed eligibility rules or final study results.[1]
